key: cord-0887000-ncqi82s0
authors: Machado, Pedro M; Lawson-Tovey, Saskia; Strangfeld, Anja; Mateus, Elsa F; Hyrich, Kimme L; Gossec, Laure; Carmona, Loreto; Rodrigues, Ana; Raffeiner, Bernd; Duarte, Catia; Hachulla, Eric; Veillard, Eric; Strakova, Eva; Burmester, Gerd R; Yardımcı, Gözde Kübra; Gomez-Puerta, Jose A; Zepa, Julija; Kearsley-Fleet, Lianne; Trefond, Ludovic; Cunha, Maria; Mosca, Marta; Cornalba, Martina; Soubrier, Martin; Roux, Nicolas; Brocq, Olivier; Durez, Patrick; Conway, Richard; Goulenok, Tiphaine; Bijlsma, Johannes WJ; McInnes, Iain B; Mariette, Xavier
title: Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
date: 2021-12-31
journal: Ann Rheum Dis
DOI: 10.1136/annrheumdis-2021-221490
sha: e858101396e86d15f5f98f92de3c7ec0cac34065
doc_id: 887000
cord_uid: ncqi82s0

OBJECTIVES: To describe the safety of vaccines against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD). METHODS: Physician-reported registry of I-RMD and non-inflammatory RMD (NI-RMDs) patients vaccinated against SARS-CoV-2. From 5 February 2021 to 27 July 2021, we collected data on demographics, vaccination, RMD diagnosis, disease activity, immunomodulatory/immunosuppressive treatments, flares, adverse events (AEs) and SARS-CoV-2 breakthrough infections. Data were analysed descriptively. RESULTS: The study included 5121 participants from 30 countries, 90% with I-RMDs (n=4604, 68% female, mean age 60.5 years) and 10% with NI-RMDs (n=517, 77% female, mean age 71.4). Inflammatory joint diseases (58%), connective tissue diseases (18%) and vasculitis (12%) were the most frequent diagnostic groups; 54% received conventional synthetic disease-modifying antirheumatic drugs (DMARDs), 42% biological DMARDs and 35% immunosuppressants. Most patients received the Pfizer/BioNTech vaccine (70%), 17% AstraZeneca/Oxford and 8% Moderna. In fully vaccinated cases, breakthrough infections were reported in 0.7% of I-RMD patients and 1.1% of NI-RMD patients. I-RMD flares were reported in 4.4% of cases (0.6% severe), 1.5% resulting in medication changes. AEs were reported in 37% of cases (37% I-RMD, 40% NI-RMD), serious AEs in 0.5% (0.4% I-RMD, 1.9% NI-RMD). CONCLUSION: The safety profiles of SARS-CoV-2 vaccines in patients with I-RMD was reassuring and comparable with patients with NI-RMDs. The majority of patients tolerated their vaccination well with rare reports of I-RMD flare and very rare reports of serious AEs. These findings should provide reassurance to rheumatologists and vaccine recipients and promote confidence in SARS-CoV-2 vaccine safety in I-RMD patients.

The WHO declared the SARS-CoV-2 outbreak a Public Health Emergency of International Concern on 30 January 2020 and a pandemic on 11 March 2020. The COVID-19 pandemic has led to a dramatic loss of human life and an unprecedented challenge to public health and healthcare systems worldwide. 1 Since the publication of the genome sequence of SARS-CoV-2 on 11 January 2020, the development of vaccines against SARS-CoV-2 accelerated at an extraordinary pace; in December 2020, two vaccines using mRNA technology (Pfizer/BioN-Tech and Moderna) and one vaccine using a nonreplicating adenoviral vector expressing the spike protein (AstraZeneca/Oxford) were authorised for use by several national and international drug regulatory bodies. 1 According to the WHO, on 17 August 2021, there were 112 candidate vaccines in human clinical trial phases and 183 candidates in preclinical development worldwide. 2 Vaccines are a key pillar of public health and the WHO estimates that vaccine immunisation currently prevents 4-5 million deaths every year. 3

Many more lives are expected to be saved with immunisation against SARS-CoV-2, which has been shown to be highly effective. [4] [5] [6] [7] [8] However, vaccination also raises questions, especially for patients with inflammatory/autoimmune rheumatic and musculoskeletal diseases (I-RMDs) and/or treated with drugs that may influence the functional competence of their immune system.

Patients with immune-mediated inflammatory diseases (including I-RMDs) were excluded from SARS-CoV-2 vaccine clinical development programmes; therefore, questions regarding the safety, effectiveness and potential measures that may increase the safety and effectiveness of vaccination against SARS-CoV-2 are unanswered. 9 10 Lack of data has led to some contradictory advice from rheumatology organisations and healthcare professionals regarding some of these vaccination aspects. 11 12 Further data will contribute to more informed decisions by patients and healthcare professionals and more robust and homogeneous evidence-based recommendations from relevant organisations. Our aim was therefore to describe the safety of vaccines against SARS-CoV-2 in people with I-RMDs.

Of note, adverse events reported in these manuscript should be considered adverse events following immunisation (AEFI), as defined by the WHO that is, 'any untoward medical occurrence which follows immunization and which does not necessarily have a causal relationship with the usage of the vaccine'. Investigating causality of AEFIs, particularly those that are more serious, is a much more challenging and complex process that should take the consistence, strength, specificity, temporal relation and biological plausibility of the association into account.

The European Alliance of Associations for Rheumatology (EULAR) Coronavirus Vaccine (COVAX) physician-reported registry was launched on 5 February 2021. Data are entered voluntarily by rheumatologists or other members of the clinical rheumatology team; patients are eligible for inclusion if they have a pre-existing I-RMD or non-inflammatory rheumatic and musculoskeletal disease (NI-RMD) and have received one or more doses of any vaccine against SARS-CoV-2. Data are entered directly into an online data entry system or transferred from national registries (for Portugal). Patients with NI-RMDs are included as a control group.

Providers were asked to report as many cases as possible of patients with rheumatic and musculoskeletal disease (RMDs) vaccinated against SARS-CoV-2, with or without adverse events. Cases could be collected in outpatient, day care or inpatient settings, with the number of reported cases per session varying depending on feasibility. When reporting only a subset of patients from, for example, a full clinic list, providers were asked to select cases randomly, in order to avoid selection bias. Furthermore, the time from vaccination to the reporting of the case/outcome was allowed to vary between individuals, and providers were also asked not to report adverse events that, in the opinion of the reporter, were definitely not related with the vaccine administration (eg, death as a consequence of road traffic accident).

Data are collected using REDCap, a secure web application for building and managing online surveys and databases. 13 14 The survey (available at https://www.eular.org/eular_covax_registry. cfm) was developed by a EULAR COVID-19 Task Force of representatives of its constituents, patients and health professionals in rheumatology and rheumatologists. Input and support was also received from the European Reference Network (ERN) on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET) and the European Reference Network on Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases Network (ERN RITA), two virtual networks involving healthcare providers across Europe, part of the EU-supported ERN initiative.

Given the registry collects anonymous non-interventional data, the UK Health Research Authority (HRA) does not class the registry as a research study (in line with the HRA decision tool), and patient consent is not required. By submitting cases, providers accept the privacy notice available on the data collection website.

The following information is collected: patients' age (years), sex at birth, country of residence, COVID-19 vaccine received, number of doses and dates, diagnosis of COVID-19 before or after vaccination, primary (and secondary) RMD diagnoses, physician global assessment of disease activity (only applicable to I-RMDs and categorised as remission/inactive disease, low, moderate or severe/high disease activity), exposure to immunomodulatory/immunosuppressive treatments at the time of vaccination, 9 I-RMD flare following vaccination and other probably/ possibly vaccine-related adverse events (AEs), including AEs of special interest. SARS-CoV-2 infections stratified by vaccination status were defined as per US Centers for Disease Control and Prevention definitions 15 : (1) infection in 'partially vaccinated' cases if occurring ≥14 days after dose one to <14 days after dose two, and (2) infection in 'fully vaccinated' cases if occurring ≥14 days after dose two or after a single-dose vaccine.

Exposure to the following immunomodulatory/immunosuppressive treatments 16 For each medication, information about changes in the original therapeutic regimen before or after COVID-19 vaccination (including stopping/holding/reducing the medication) is also collected.

For patients with I-RMDs, information about flares is collected, namely: (1) type of flare (fever, weight loss, increase in fatigue, increase in dryness, enlarged lymph nodes, arthralgia, arthritis flare, cutaneous, pulmonary, renal, neurological, muscular, cardiac, gastrointestinal or haematological flare or other type of flare); (2) severity of flare (mild/minor, moderate, severe/major without hospitalisation and severe/major with hospitalisation);

(3) information about changes in medication (including dosage increase) due to the flare; and (4) period of time between vaccination and the flare.

Two main types of AEs are collected: 1. Early AEs within 7 days from vaccination (reactogenicity):

pain, redness or swelling at the site of injection, generalised muscle or joint pain, headache, fever, chills, fatigue, vomiting and diarrhoea. 2. AEs of special interest: collected based on organ/system affected, with the possibility to add free-text descriptors. Information about the period of time between vaccination and the AE, degree of confidence in the relationship between the AE and the COVID-19 vaccine, outcome (ongoing/continuing, recovered/resolved without sequelae, recovered/resolved with sequelae, death and unknown) and if the AE was serious or not is also collected.

Serious AEs (SAEs) are further categorised into six possible groups: resulting in an important medical event, resulting in hospitalisation or prolongation of existing hospitalisation (hospitalisation being defined as at least 24 hours in a hospital or an overnight stay), life-threatening event, resulting in persistent or significant disability/incapacity, resulting in death or resulting in congenital anomaly/birth defect.

Descriptive statistics, including means and SD, frequencies and proportions, are used to describe the data. Data are presented separately for patients with I-RMD and NI-RMD. Crystal arthropathies were included in the NI-RMD group as these patients are not usually treated with immunomodulatory/immunosuppressive drugs. Missing data were treated as missing.

Between 5 February 2021 and 27 July 2021, 5121 cases were submitted to the EULAR COVAX registry (table 1) . Seventy per cent of these cases were female, the mean age was 61.6 (SD 15.2), and over half of the cases were over the age of 60 years (56%). Cases were submitted from 30 countries, the majority from France (40%), Italy (16%) and Portugal (14%). Providers were from diverse rheumatology practices, including academic and non-academic centres, and a minority of private practices. The I-RMD group made up 90% of all cases (n=4604), with a mean age of 60.5 (SD 15.1) and 68% of this group were female. The NI-RMD group (10%, n=517) had a higher percentage of female cases (77%) and a higher mean age (71.4, SD 12.5), with 80% of the group having an age over 60 years. Mean time between first vaccine dose and case reporting was 66 days (SD 40), 66 days (SD 40) in the I-RMD group and 64 days (SD 40) in the NI-RMD group.

Over half of the cohort had an inflammatory joint disease as their primary RMD diagnosis (58%), 18% had a connective tissue disease, 12% vasculitis and 2% another I-RMD (table 2). The most common I-RMDs were rheumatoid arthritis (33%), axial spondyloarthritis (11%) and psoriatic arthritis (10%). Osteoarthritis (5%) and osteoporosis (2%) were the most frequent NI-RMDs.

The majority of the I-RMD group had minimal (41%) or low (28%) disease activity, although these data were missing in 17% of cases.

Fifty-four per cent of the I-RMD group received csDMARDs, 42% bDMARDs and 35% immunosuppressants. The most common individual medications were methotrexate (MTX; 34%), GCs (30%) and TNF-inhibitors (25%). Overall, there were few medication changes either before or after vaccination; however, changes were more prevalent in some drugs than others. Seven per cent of patients taking rituximab and IL-6 inhibitors held their medication before vaccination, 6% of TNFinhibitor patients held the drug prior to vaccination and 6% and 4% of MTX cases held the medication before and after vaccination, respectively (table 2) .

Most patients received the Pfizer/BioNTech vaccine (70%), 17% had the AstraZeneca/Oxford and 8% the Moderna vaccine (table 3) . One quarter of cases had one vaccine dose, whereas almost three quarters (74%) had two and 1% had three. Mean time between the first and second dose of the vaccine (if applicable) was 34 days (SD 62), 33 days (SD 18) in the I-RMD group and 43 days (SD 189) in the NI-RMD group. Mean time between the first and second vaccine doses in the Pfizer group was 28 days (SD 12), 30 days (SD 8) in the Moderna group and 78 days (SD 14) in the AstraZeneca/Oxford group.

The split of vaccine types, doses and postvaccination SARS-CoV-2 infection was similar between the I-RMD and NI-RMD groups (table 3) , although 12 I-RMD cases received a combination of vaccines (Pfizer/BioNTech and either AstraZeneca/ Oxford or CoronaVac/Sinovac).

SARS-CoV-2 infection after vaccination occurred in 46 cases (0.9%), with 42 cases occurring in the I-RMD (0.9%) and 4 Epidemiology cases occurring in the NI-RMD group (0.8%); however, only 21 cases (0.7%) occurred in fully vaccinated patients (n=18, 0.7%; n=3, 1.1%; in the I-RMD and NI-RMD group, respectively).

When stratified by vaccine type, the percentage of cases with postvaccination SARS-CoV-2 infection was equal across vaccine types in the I-RMD group (online supplemental table 1) but only reported following the Pfizer/BioNTech vaccine or other vaccine types in the NI-RMD group (online supplemental table 2), though this is explained by the low number of cases vaccinated with Oxford/AstraZeneca and Moderna in the NI-RMD group.

Flare following vaccination was reported in 4.4% (n=204) of I-RMD cases, though these data were missing in 15% of cases. Mean time between the most recent vaccine dose (prior to flare) and the flare was 6 days (SD 8). The most common flares were arthritis flare, polyarthralgia and increase in fatigue (2.1%, 1.8%, and 0.7% of the I-RMD cohort, respectively). Most flares were mild (1.5%) or moderate (2.1%), with 29 cases (0.6%) being severe and 68 cases (1.5%) having started a new medication or increased existing medication dosage as a result of the flare (table 3) .

The percentage of cases reporting a flare, flare severity and medication changes due to the flare were consistent among different vaccines (online supplemental table 1). The percentage of flares was slightly higher in patients with moderate/high disease activity (5.2%) compared with patients in remission/low disease disease activity (4.8%), with similar results observed for severe flares (1.0% vs 0.7%), though disease activity information was missing in 17% of cases. These findings raise the possibility of an association between higher disease activity and higher flare rate.

When stratified by I-RMD group (table 4) , patients with inflammatory joint diseases experienced a slightly higher percentage of flares compared with the connective tissue disease and vasculitis groups (5.1% vs 3.1% vs 3.2%, respectively). Flare prevalence was similar across most medication groups in I-RMD cases (table 5) , although patients on monotherapy or combination therapies of TNF-inhibitors (5.5%), other biologicals (5.3%), other csDMARDs (excluding methotrexate) (4.7%) and tsDMARDs (4.6%) reported a slightly higher percentage of flares than other medication groups (2.7%-3.6%). The lower flare rate was observed for rituximab and immunosuppressants (both 2.7%).

There were possible/probable vaccine-related AEs in 37% of all cases, 37% in the I-RMD group and 40% in the NI-RMD group. The majority were early AEs, mostly pain at injection site (19%), fatigue (12%), generalised muscle pain (7%) and fever (7%). Overall, the pattern and proportion of early AEs was similar between I-RMD and NI-RMD cases (table 3) .

When I-RMD cases were stratified by vaccine type (online supplemental table 1), the percentage of AEs was similar across the group (32%-37%), except for Moderna, where a slightly higher percentage was observed (42%). The percentages of most individual types of early AEs were also similar across vaccines; however, a larger proportion of Moderna (26%) and a lower proportion of AstraZeneca/Oxford cases (12%) had pain at the injection site, and higher percentages of AstraZeneca/Oxford (4) 3 (1) 200 (4) France 1838 (40) 232 (45) 2070 (40) Italy 615 (13) 194 (38) 809 (16) Latvia 107 (2) 19 (4) 126 (2) Monaco 296 (6) 36 (7) 332 (6) Portugal 737 (16) -737 (14) Ireland 76 (2) 7 (1) 83 (2) Romania 61 (1) 4 (1) 65 (1) Slovak Republic 204 (4) 11 (2) 215 (4) Spain 164 (4) 5 (1) 169 (3) Turkey (1) Other countries* 159 (3) 4 (1) 163 (3) All values are n (%) unless stated otherwise. *Other countries classified as those who submitted <50 cases: Albania, Australia, Austria, Croatia, Czechia, Estonia, Germany, Greece, Hungary, Lithuania, Luxembourg, Netherlands, Republic of Moldova, Russian Federation, Slovenia, Switzerland, Ukraine and USA. RMDs, rheumatic and musculoskeletal diseases. (7) Primary anti-phospholipid syndrome 26 (1) Sjogren's syndrome 223 (4) Systemic sclerosis 162 (3) Idiopathic inflammatory myopathy (myositis) 69 (1) Mixed connective tissue disease 37 (1) Undifferentiated connective tissue disease 43 (1) Ehlers In the NI-RMD group (online supplemental table 2), the prevalence of AEs was more variable across vaccine types, with Severe -Important medical event

Severe -Hospitalisation (or prolongation of existing hospitalisation)

Severe -Life-threatening 1 (<1) 1 (<1) 1 (<1) 1 (<1)

All values are N (%) unless stated otherwise.

AEs, adverse events; combi, combination therapy; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; mono, monotherapy; MTX, methotrexate; RMD, rheumatic and musculoskeletal disease; RTX, rituximab; TNF, tumour necrosis factor; tsDMARD, targeted synthetic disease-modifying antirheumatic drug. the most salient difference between vaccines being the lower percentages of Pfizer/BioNTech (13%) and AstraZeneca/Oxford (10%) cases that experienced pain at injection site compared with 50% of Moderna vaccinated cases. There were 149 AEs of special interest (2.9% of all patients), 112 (2.4%) in the I-RMD group and 37 (7.2%) in the NI-RMD group, and most of the AEs resolved/recovered without sequelae (100 cases, 2.0% of all patients; n=75, 1.6% in the I-RMD group; n=25, 4.8% in the NI-RMD group). Both in the I-RMD and NI-RMD group, a larger diversity of AEs of special interest were seen following vaccination with Pfizer/BioNTech, reflecting the higher number of cases receiving this vaccine. However, there were no salient differences between vaccines or between patients with I-RMD and NI-RMD (table 6) . Mean time between the most recent vaccine dose (prior to AE of special interest) and the AE of special interest was 7 days (SD 17), 7 days (SD 15) in the I-RMD group and 8 days (SD 21) in the NI-RMD group.

SAEs were rare (n=27, 0.5% of all patients) and more prevalent in the NI-RMD group (n=10, 1.9%) than in the I-RMD group (n=17, 0.4%). Among these 27 SAEs, three were life threatening, all occurring in Pfizer/BioNTech vaccine recipients in the I-RMD group. These were two cases of 'cardiaccoronary artery disease' events and one 'gastrointestinal -liver injury' event; all three events recovered/resolved, though one cardiac event and the 'gastrointestinal -liver injury' event recovered/resolved with sequelae (table 6) .

There were six instances of SAEs resulting in hospitalisation in the I-RMD group, all in Pfizer/BioNTech vaccine recipients. One of these was a 'haematologic -peripheral deep vein thrombosis' event, one was a 'haematologic -stroke' event, one was an 'immunological -skin or mucosal' event (erythema nodosum), two were 'viral infection -herpes zoster/shingles' events and finally one 'other -neck swelling event' (table 6) .

Eight SAEs classified as serious important medical events were seen in the I-RMD group, occurring in Pfizer/BioNTech (n=7) and AstraZeneca/Oxford (n=1) vaccine recipients. There were three 'immunological -skin or mucosal' events (gingivitis, pharyngitis and bullous leg rash), one 'cardiac -arterial hypertension', one 'malaise', one 'neurological -hemiparesis', one 'other -possible cardiac' event (dyspnoea) and one 'viral infectionherpes zoster/shingles' event (table 7) .

There were two SAEs resulting in hospitalisation in the NI-RMD group: one an 'immunological -vasculitides' event (giant cell arteritis), in a Moderna vaccine recipient, and one other possible cardiac event (dyspnoea), in a Pfizer/BioNTech vaccine recipient. Eight events were classified as important medical events: one 'arterial hypertension' event, two 'immunological -arthritis' events, a 'gastrointestinal -liver injury' event, one 'immunological -vasculitides' event (polymyalgia rheumatica-like syndrome), one 'neurological -syncope', one 'neurological -vertigo' and one 'tendons and joints' event (frozen shoulder) (table 7) .

SAEs resulting in death, persistent or significant disability/ incapacity or congenital anomaly/birth defect were neither reported in the I-RMD group nor in the NI-RMD group.

Of note, we are not aware of any cases of vaccine-induced immune thrombotic thrombocytopenia in this cohort, an exceedingly rare complication described in the general population with the AstraZeneca and Janssen vaccines. One case of isolated thrombocytopenia after the first dose of the AstraZeneca vaccine was reported in a young (<30 years old) female patient with mixed connective tissue disease; however, this was a transient laboratory change without clinical repercussion. Regarding myocarditis and pericarditis, a rare complication associated with mRNA vaccines, this was reported after the second dose of the Pfizer vaccine in a young (<30 years old) female patient with systemic lupus erythematosus, and she recovered without sequelae from this event.

We created the largest international case series of people with I-RMDs vaccinated against SARS-CoV-2 and report that the safety profile of vaccines against SARS-CoV-2 in this population was reassuring. The overwhelming majority of patients tolerated their vaccination well with rare reports of I-RMD flare (4.4%, 0.6% severe) and very rare reports of SAEs (0.4%). Changes in medication due to flare were also rare (1.5% of I-RMD patients). Most AEs were the same and in similar proportion as observed in patients with NI-RMDs (and the general population); they were non-serious and involved transient local and systemic symptoms.

Regarding flares, the data suggest that the risk of I-RMD flare following vaccination is low and not more strongly associated with any particular type of vaccine, with observed percentages being compatible with the natural history of the disease rather than necessarily caused by vaccines against SARS-CoV-2. 17 Regarding early AEs (reactogenicity), both the profile and frequency of AEs were similar between I-RMD and NI-RMD cases. The frequency and type of early AEs was also similar between vaccines, both for the I-RMD and NI-RMD groups, with the possible exception of a slightly higher proportion of pain at the injection site with the Moderna vaccine (both in the I-RMD and NI-RMD group). Both the flare and AE data are in line with previous smaller studies in patients with I-RMDs (13 to 2860 patients, with the largest cohort being patient reported rather than physician reported). Regarding AEs of special interest, they were infrequent and their proportion tended to be smaller in the I-RMD group compared with the NI-RMD group and in line with rates reported in trials in the general population. There was significant diversity in terms of AEs of special interest observed both in I-RMD and NI-RMD cases, particularly in I-RMD cases, reflecting the higher number of cases in this subgroup of patients; however, no salient differences between the I-RMD and NI-RMD groups were found, and no clustering of AEs of special interest was observed.

While the primary aim of our study was to collect safety data among I-RMD patients receiving vaccines against SARS-CoV-2, we also collected data regarding breakthrough infections and found that these occurred very infrequently, particularly in fully vaccinated patients (0.7% and 1.1% of cases in the I-RMD and NI-RMD group, respectively). A more detailed report describing cases of breakthrough infections in patients with I-RMDs from the EULAR COVAX and COVID-19 registries, including details about vaccines administered, exposure to anti-rheumatic medications and outcome of breakthrough infections, has previously been published. 40 We found that temporary discontinuation of antirheumatic medications was infrequent. This attitude towards antirheumatic medications might reflect the fact that this is largely a European registry. Contrary to the American College of Rheumatology, who recommended holding methotrexate, JAK inhibitors, abatacept, mycophenolate mofetil and rituximab in certain patients with controlled disease, 12 EULAR did not advise temporarily stopping or adjusting the timing of any of these medications (with the exception of rituximab) relative to when the vaccine against SARS-CoV-2 is administered. 11 Future studies are needed to determine if changes in certain antirheumatic medication Epidemiology Epidemiology regimens might increase the effectiveness of vaccines against SARS-CoV-2 while balancing the risk of disease flare (and the need for additional treatment of the flare, such as GCs). Strengths of this study include the rapid dissemination via European networks (EULAR, ERN ReCONNET and ERN RITA) that resulted in a large number of cases reported by rheumatologists, internists or associated healthcare professionals over a short period of time. However, our study has important limitations. The COVAX registry relies on voluntary case submission, leading to possible selection bias in the data, and concerns regarding the generalisability of the results. However, this could in principle have led to over-reporting of flares and AEs; therefore the low rate of flares/AEs consistent with other publications is reassuring. Moreover, the underlying risk of flare also differs among RMDs, which may influence the overall flare rate and differences between conditions. Furthermore, dissemination was more effectively achieved in certain European countries (eg, France, Italy and Portugal), and reporting was also influenced by differences in vaccine availability and access across European countries, which has resulted in a significantly higher proportion of cases vaccinated with the Pfizer vaccine, limiting comparisons between vaccines. Time between vaccination and case reporting is also variable and sometimes relatively short, limiting data interpretation and not allowing us to draw any conclusions regarding the long-term safety profile of vaccines against SARS-CoV-2. Moreover, a control group of patients with I-RMDs is not available, and the sample size of patients with NI-RMDs is substantially smaller. For some signs/symptoms, it can be difficult to determine if the event should be considered an I-RMD flare or simply a transient side effect of the vaccine (eg, polyarthralgia); in our study, this decision was left to the reporting physician, which can be considered a study limitation. Similarly, systemic flares were also based on the report of the physician without collection of more detailed evidence of the flare (eg, results of investigations). Finally, the information regarding SARS-CoV-2 infection after vaccination is based on the report of physicians/healthcare providers, and no information is provided concerning the presence or the titre of postvaccine antibodies. Importantly, no causal conclusions regarding vaccination and the development of flares/AEs can firmly be drawn from this dataset.

In conclusion, our findings should provide reassurance to rheumatologists, other health professionals and vaccine recipients and and promote confidence in SARS-CoV-2 vaccine safety in people with I-RMDs. The rate of severe flares was very low (0.6%). Likewise, the rate of SAEs in I-RMDs was 0.4%, comparable and even lower than in patients with NI-RMDs (1.1%), suggesting that the tolerance to the vaccine was not different between the groups. Interestingly, in clinical trials of mRNA, inactivated and non-replicating vector vaccines against SARS-CoV-2 in the general population, the pooled rates of SAEs were very similar to our study, ranging from 0.4% to 0.6% in the vaccine group, and from 0.5% to 0.6% in the control group, 41 suggesting that these SAEs are not necessarily causally related to the vaccine and might be coincidental observations. However, although the mean time between first vaccine dose and case reporting of 66 days in our report is not very different from the follow-up period in some of the vaccination trials, this is an indirect comparison that should be interpreted with caution, because the follow-up period in our study was allowed to vary, and there are also important differences between follow-up periods among vaccination trials (that typically do not go beyond 6 months). Future studies should address the effectiveness and safety of vaccines against SARS-CoV-2 in patients with I-RMDs and/or patients taking immunosuppressive/immunomodulatory drugs, both in controlled and general surveillance settings. 

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates

World Health Organization. COVID-19 vaccine tracker and landscape

World Health Organization. Immunization coverage

BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2

Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases

Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines

View points on SARS-CoV-2 vaccination in patients with RMDs

American College of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3

The REDCap Consortium: building an international community of software platform partners

Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support

Cdc COVID-19 study shows mRNA vaccines reduce risk of infection by 91 percent for fully vaccinated people

Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs

Improved flare and remission pattern in rheumatoid arthritis over recent decades: a population-based study

Humoral response to pfizer mRNA vaccine against SARS CoV2, in patients with autoimmune inflammatory rheumatic diseases and the impact on the rheumatic disease activity

Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases

Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the International VACOLUP study

Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City

Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis

Incidence of disease flare after BNT162b2 coronavirus disease 2019 vaccination in patients with rheumatoid arthritis in remission

Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey

Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series

Disease flare and Reactogenicity in patients with rheumatic and musculoskeletal diseases following two-dose SARS-CoV-2 messenger RNA vaccination

Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases

Safety of BNT162b2 mRNA COVID-19 vaccine in a cohort of elderly, immunocompromised patients with systemic vasculitis

Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a crosssectional study

Evaluation of immune response and disease status in SLE patients following SARS-CoV-2 vaccination

Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial

BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus

ImmunosuppressiveTherapies differently modulate Humoral-and T-cell-specific responses to COVID-19 mRNA vaccine in rheumatoid arthritis patients

Preliminary data on post market safety profiles of COVID 19 vaccines in rheumatic diseases: assessments on various vaccines in use, different rheumatic disease subtypes, and immunosuppressive therapies: a Two-Centers study

Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 global rheumatology alliance vaccine survey

SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases

Evaluation of the safety profile of COVID-19 vaccines: a rapid review

Acknowledgements We wish to thank all healthcare providers who entered data into the registry.Contributors PMM is responsible for the overall content as the guarantor, and accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish. PMM and SL-T had access to the study data, developed the figures and tables, wrote the first draft of the manuscript and vouch for the data and analyses. PMM, KLH, LG, AR, BR, CD, EH, EV, ES, GRB, GKY, JAG-P, JZ, LF, LK-F, MCU, MM, MCo, MS, NR, OB, PD, RC, TG and XM contributed to data collection and interpretation of the data. PMM, SL-T, AS, EFM, KLH, LG, LC, EH, MM, GRB, JWJB, IBM and XM contributed to study design and questionnaire development. PMM directed the work and had final responsibility for the decision to submit for publication. All authors contributed intellectual content during the drafting and revision of the work and approved the final version to be published.Competing interests PMM has received consulting/speaker's fees from Abbvie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, all unrelated to this manuscript, and is supported by the National Institute for Health Research (NIHR), University College London Hospitals (UCLH), Biomedical Research Centre. SL-T does not report conflicts of interest. AS has received personal fees from lectures for AbbVie, MSD, Lilly, Roche, BMS and Pfizer. EFM has received personal consultant fees from Boehringer Ingelheim Portugal, Lda; LPCDR received support for specific activities: grants from Abbvie, Novartis, Lilly Portugal, Amgen Biofarmacêutica, Grünenthal S.A., MSD, Medac and from A. Menarini Portugal -Farmacêutica, S.A.; grants and non-financial support from Pfizer, and non-financial support from Grünenthal GmbH, outside the submitted work. KLH has received non-personal speaker's fees from Abbvie and grant income from BMS, UCB and Pfizer, all unrelated to this manuscript, and is supported by the NIHR Manchester Biomedical Research Centre. LG has received personal consultant fees from AbbVie, Amgen, BMS, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis and UCB, and grants from Amgen, Galapagos, Lilly, Pfizer, Sandoz and Sanofi, all unrelated to this manuscript. LC has not received any fees or personal grants from any laboratory, but her institute works by contract for laboratories among other institutions, such as Abbvie Spain, Eisai, Gebro Pharma, Merck Sharp This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. Epidemiology Eric Hachulla http://orcid.org/0000-0001-7432-847X Gerd R Burmester http://orcid.org/0000-0001-7518-1131 Jose A Gomez-Puerta http://orcid.org/0000-0001-8177-702X Lianne Kearsley-Fleet http://orcid.org/0000-0003-0377-1575 Ludovic Trefond http://orcid.org/0000-0001-5454-903X Patrick Durez http://orcid.org/0000-0002-7156-2356 Richard Conway http://orcid.org/0000-0003-2538-3362 Johannes WJ Bijlsma http://orcid.org/0000-0002-0128-8451 Xavier Mariette http://orcid.org/0000-0002-4244-5417

Ethics approval This study involves human participants but given that the Registry collects anonymous non-interventional data, the UK Health Research Authority (HRA) does not class the Registry as a research study (in line with the HRA decision tool) and patient consent is not required.Provenance and peer review Not commissioned; externally peer reviewed.Data availability statement Data are available on reasonable request.Applications to access the data should be made to the European Alliance of Associations for Rheumatology (EULAR).Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.